Characterization of tumour mutation burden in patients with non‐small cell lung cancer and interstitial lung disease
暂无分享,去创建一个
K. Yamaguchi | M. Endo | T. Nagashima | M. Kusuhara | T. Naito | Y. Ohde | Toshiaki Takahashi | H. Kojima | M. Serizawa | T. Mizuno | K. Ohshima | K. Urakami | H. Konno | M. Isaka | Haruki Kobayashi
[1] T. Maeyama,et al. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis , 2018, Thoracic cancer.
[2] A. Otsuka,et al. Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. , 2018, JCO precision oncology.
[3] Nikolaus Schultz,et al. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.
[4] Young Hak Kim,et al. Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease , 2018, Thoracic cancer.
[5] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[6] T. Morimoto,et al. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. , 2017, Lung cancer.
[7] K. Kinzler,et al. Evaluating the evaluation of cancer driver genes , 2016, Proceedings of the National Academy of Sciences.
[8] Kui Wu,et al. Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma , 2016, Oncotarget.
[9] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[10] Shandra L. Protzko,et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.
[11] Nicholas B. Larson,et al. PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data , 2013, Bioinform..
[12] T. Higami,et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? , 2008, The Journal of thoracic and cardiovascular surgery.
[13] David A Lynch,et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. , 2005, American journal of respiratory and critical care medicine.
[14] D. Spandidos,et al. MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis , 2002, Journal of cellular and molecular medicine.